--------------------------------------------------------------------------------

Exhibit A

Asset Purchase Agreement

        This ASSET PURCHASE AGREEMENT (this “Agreement”) dated as of July 28,
2003 by and among the Siegel Family Revocable Trust (the “Trust”) and Medical
Technology Systems, Inc., a Delaware corporation (the “Company”). The Trust and
the Company are collectively referred to as the “Parties.”

BACKGROUND

        The Trust licenses the Patent Rights (as defined below) to the Company
pursuant to the License Agreement (as defined below). The Company currently owes
the Trust $348,000 in royalty payments due under the License Agreement. The
Trust desires to sell to the Company, and the Company desires to purchase, the
Patent Rights (as defined below) from the Trust in exchange for the payment by
the Company to the Trust of the Purchase Price (as defined below), all in
accordance with the terms and conditions set forth in this Agreement.

        In consideration of the mutual covenants and agreements set forth below,
the Parties agree as follows:

TERMS

    1.        Definitions.   For the purposes of this Agreement, the following
terms shall have the following meanings:

               (a)     “Devices” shall mean the equipment and supplies covered
by the Patent Rights.

               (b)     “Know how” shall mean all operating details and
instructions, both written and oral, of the Trust for the manufacture, use,
promotion and sale of the Devices.

               (c)        “License Agreement” means that certain License
Agreement, dated as of October 14, 1986, by and between the Trust and DRG
Consultants, Inc. (“DRG”) (which was assigned by DRG to the Company on October
14, 1986 pursuant to an Agreement and Plan of Reorganization between the Company
and DRG), as amended on September 2, 1990 pursuant to an Agreement between the
Company and the Trust.

               (d)        “Patent Rights” shall mean (i) the patents and patent
applications set forth on the Patent Rights Schedule owned or controlled by the
Trust and related to equipment and supplies used in packaging medication in
punch cards (which is the basis of the equipment and processes which the Company
uses and sells in its business), and (ii) “know how”.

               (e)        “Securities Act” means the Securities Act of 1933, as
amended and the regulations promulgated thereunder.

               (f)        “Security Interest” means any mortgage, pledge, lien,
encumbrance, charge, or other security interest, other than (a) mechanic’s,
materialmen’s, and similar liens, (b) liens for taxes not yet due and payable or
for taxes that the taxpayer is contesting in good faith through appropriate
proceedings, (c) purchase money liens and liens securing rental payments under
capital lease arrangements, and (d) other liens arising in the ordinary course
of business and not incurred in connection with the borrowing of money.

2.

--------------------------------------------------------------------------------

    2.        Purchase and Sale. Upon the terms and subject to the conditions of
this Agreement, the Trust sells to the Company, and the Company purchases from
the Trust, the Patent Rights, including all of the Trust’s entire right, title
and interest, in all countries throughout the world, including the rights to
claim convention priority, in and to any and all improvements disclosed in the
Patents Rights and the right to sue for past, present and future patent
infringement of the Patent Rights.

    3.        Purchase Price and Forgiveness of Royalties. Simultaneous with the
execution of this Agreement, the Company is paying to the Trust $1,480,000 (the
“Purchase Price”) by delivery of a promissory note (the “Note”) in substantially
the form attached to this Agreement as Exhibit A in the aggregate principal
amount of $1,480,000. In consideration for the payment by the Company of the
Purchase Price to the Trust, the Trust forgives the $348,000 in royalty payments
currently due from the Company to the Trust under the License Agreement.

    4.        Company’s Closing Deliveries and Obligations. Simultaneous with
the execution of this Agreement, the Company shall deliver to the Trust:

               (a)        a certificate representing the Note; and

               (b)        an Assignment and Assumption Agreement, in the form
attached as Exhibit B (the “Assignment and Assumption Agreement”), executed by
the Company.

    5.        Trust’s Closing Deliveries. Upon the execution of this Agreement,
the Trust shall deliver to the Company the Assignment and Assumption Agreement,
executed by the Trust.

    6.        Representations and Warranties of the Company. The Company makes
the following representations and warranties to the Trust:

               (a)        Existence. The Company is duly organized, validly
existing and in good standing under the laws of the State of Delaware, and is
duly qualified to do business and is in good standing under the laws of each
jurisdiction where such qualification is required.

               (b)        Authorization. The Company has all necessary corporate
power and has taken all necessary corporate action required for the due
authorization, execution, delivery and performance by the Company of this
Agreement, the Company Transaction Documents (as defined below) and for the due
authorization, issuance and delivery of the Note.

               (c)        No Breach. The execution, delivery and performance of
this Agreement and any other agreement or instrument executed by the Company in
connection with this Agreement, including without limitation, the Note (the
“Company Transaction Documents”), constitutes a valid and binding obligation of
the Company, enforceable in accordance with its terms subject to the effect of
bankruptcy, insolvency, reorganization or other similar laws and to general
principles of equity (whether considered in proceedings at law or in equity).

2.

--------------------------------------------------------------------------------

The execution and delivery by the Company of the Company Transaction Documents
to which the Company is a party, the issuance of the Note under this Agreement,
and the fulfillment of and compliance with the respective terms of this
Agreement by the Company, do not and shall not (i) conflict with or result in a
breach of the terms, conditions or provisions of, (ii) constitute a default
under, (iii) result in the creation of any lien, security interest, charge or
encumbrance upon the Company’s capital stock or assets pursuant to, (iv) give
any third party the right to modify, terminate or accelerate any obligation
under, (v) result in a violation of, or (vi) require any authorization, consent,
approval, exemption or other action by or notice or declaration to, or filing
with, any court or administrative or governmental body or agency pursuant to the
Company’s certificate of incorporation or bylaws, or any law, statute, rule or
regulation to which the Company is subject, or any agreement, instrument, order,
judgment or decree to which the Company is subject.

               (d)        Governmental Consent, etc. No permit, consent,
approval or authorization of, or declaration to or filing with, any governmental
authority (except as may be required under federal and state securities laws) is
required in connection with the execution, delivery and performance by the
Company of this Agreement or the other agreements contemplated by this
Agreement, or the consummation by the Company of any other transactions
contemplated by this Agreement, except as expressly contemplated in this
Agreement or in the Schedules to this Agreement.

    7.        Representations and Warranties of the Trust. The Trust makes the
following representations and warranties to the Company.

               (a)        Authority. The execution, delivery and performance of
this Agreement and any other agreement or instrument executed by the Trust in
connection with this Agreement (the “Trust Transaction Documents”), constitutes
a valid and binding obligation of the Trust.

               (b)        No Breach. The execution, delivery and performance by
the Trust of the Trust Transaction Documents to which the Trust is a party and
the fulfillment of and compliance with the respective terms of this Agreement by
the Trust, do not and shall not (i) conflict with or result in a breach of the
terms, conditions or provisions of, (ii) constitute a default under,
(iii) result in the creation of any lien, security interest, charge or
encumbrance upon the Trust’s assets pursuant to, (iv) give any third party the
right to modify, terminate or accelerate any obligation under, (v) result in a
violation of, or (vi) require any authorization, consent, approval, exemption or
other action by or notice or declaration to, or filing with, any court or
administrative or governmental body or agency, or any law, statute, rule or
regulation to which the Trust is subject, or any agreement, instrument, order,
judgment or decree to which the Trust is subject.

               (c)        Title to Assets. Except for the rights granted to the
Company pursuant to the License Agreement, the Trust has exclusive ownership of,
free and clear of Security Interests, with full right to use, sell, license,
sublicense, dispose of, and bring actions for infringement of, or possesses
licenses or other rights to use, the Patent Rights.

3.

--------------------------------------------------------------------------------

               (d)        Intellectual Property.

                           (i)        The Patent Rights do not infringe any
patent, trademark, copyright, trade secret rights of any third parties or any
other intellectual property rights of any third parties. The Trust has not
received written notice from any third party asserting that the Patent Rights
are invalid or unenforceable.

                           (ii)         Except for the license granted to the
Company pursuant to the License Agreement, the Trust has not licensed or
otherwise granted permission to use the Patent Rights to any person or entity,
other than the Trust.

                           (iii)         There are no actions, suits,
proceedings, orders, investigations or claims pending or, to the Trust’s
knowledge, threatened against or affecting the Trust, or pending or threatened
by the Trust against any third party, at law or in equity, or before or by any
governmental department, commission, board, bureau, agency or instrumentality in
connection with or related to the Patent Rights.

                           (iv)         The Trust hereby covenants that no
assignment, sale, agreement or encumbrance has been or will be made or entered
into which would conflict with this Agreement.

               (e)        Investment. The Trust is acquiring the Note for its
own account for the purpose of investment and not with a view to or for sale in
connection with any distribution of the Note. The Trust further represents that
it understands that the Note has not been registered under the Securities Act by
reason of its issuance in a transaction exempt from the registration
requirements of the Securities Act. The Trust represents that it understands
that the Note may only be transferred pursuant to a registration statement or an
exemption from registration and there is not currently any public market for the
Note. The Trust is an Accredited Investor (as defined by the Securities Act Rule
501(a)) and is able to bear the economic risk and lack of liquidity inherent in
holding the Note.

               (f)        Investigation by the Trust. The Trust has conducted
its own independent investigation, review and analysis of the business,
operations, assets, liabilities, results of operations, financial condition, and
prospects of the Company which included the review of the Company’s most recent
Form 10-K filed with the Securities and Exchange Commission on June 30, 2003. In
entering into this Agreement, the Trust acknowledges that it has relied solely
upon its own knowledge, investigation, review and analysis of the Company, and
not on any representations of the Company or its representatives.

    8.        Restrictive Legend. The certificate representing the Note subject
to this Agreement shall have the following legends attached:

  THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW.
THESE SECURITIES MAY NOT BE OFFERED, SOLD, OR OTHERWISE TRANSFERRED IN ANY
MANNER ABSENT EITHER REGISTRATION UNDER THE ACT AND UNDER EVERY APPLICABLE STATE
SECURITIES LAW, OR AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER AND ITS
COUNSEL THAT REGISTRATION UNDER THOSE LAWS IS NOT REQUIRED.

4.

--------------------------------------------------------------------------------

The Trust irrevocably appoints and designates the person who is from time to
time the Secretary of the Company as such person’s attorney-in-fact, for and on
its behalf, to cause the legend described above to be placed on the certificate
representing the Note.

    9.        Indemnification. Subject to Section 10:

               (a)     Indemnification of the Trust. The Company shall indemnify
the Trust and hold the Trust harmless from and against any and all damages,
losses, deficiencies, actions, demands, judgments, costs and expenses (including
reasonable attorneys’ and accountants’ fees) (collectively, “Losses”) of or
against the Trust resulting from (i) any misrepresentation or breach of warranty
in this Agreement or (ii) any nonfulfillment of any agreement or covenant
contained in this Agreement.

               (b)     Indemnification of the Company. The Trust shall indemnify
the Company and its officers, directors and shareholders (collectively, the
“Company Indemnified Parties”) and hold each of the Company Indemnified Parties
harmless from and against any and all Losses of or against the Company
Indemnified Parties resulting from (i) any misrepresentation or breach of
warranty in this Agreement on the part of the Trust or (ii) any nonfulfillment
of any agreement or covenant contained in this Agreement.

               (c)     Procedure Relative to Indemnification.

                           (i)         In the event that any Party shall claim
that it is entitled to be indemnified pursuant to the terms of this Section 9
(the “Claiming Party”), the Claiming Party shall so notify the Party against
which the claim is made (the “Indemnifying Party”) in writing of such claim
within thirty days after the Claiming Party receives notice of any action,
proceeding, demand or assessment or otherwise has received notice of any claim
of a third party that may reasonably be expected to result in a claim for
indemnification by the Claiming Party against the Indemnifying Party; provided,
however, that failure to give such notification shall not affect the
indemnification provided hereunder except to the extent the Indemnifying Party
shall have been actually prejudiced as a result of such failure. Such notice
shall specify the breach of representation, warranty, agreement or covenant
claimed by the Claiming Party and the Losses incurred by, or imposed upon the
Claiming Party on account thereof. If such Losses are liquidated in amount, the
notice shall so state and such amount shall be deemed the amount of the claim of
the Claiming Party. If the amount is not liquidated, the notice shall so state
and in such event a claim shall be deemed asserted against the Indemnifying
Party on behalf of the Claiming Party, but no payment shall be made on account
thereof until the amount of such claim is liquidated and the claim is finally
determined.

                           (ii)         The following provisions shall apply to
any claim of the Claiming Party which is based upon (A) a suit, action or
proceeding filed or instituted by any third party, or (B) any form of proceeding
or assessment instituted by any governmental entity.

5.

--------------------------------------------------------------------------------

                                         (1)     If any third party shall notify
any Claiming Party with respect to any matter (a “Third Party Claim”) which may
give rise to a claim of indemnification from the Indemnifying Party under this
Section 9, then the Claiming Party shall promptly notify the Indemnifying Party
thereof in writing; provided, however, that no delay on the part of the Claiming
Party in notifying the Indemnifying Party shall relieve the Indemnifying Party
from any obligation hereunder unless (and then solely to the extent) the
Indemnifying Party is prejudiced by such delay.

                                         (2)     The Indemnifying Party will
have the right to assume the defense of the Third Party Claim with counsel of
its choice reasonably satisfactory to the Claiming Party at any time within 15
days after the Claiming Party has given notice of the Third Party Claim;
provided, however, that the Indemnifying Party must conduct the defense of the
Third Party Claim actively and diligently thereafter in order to preserve its
rights in this regard; and provided further that the Claiming Party may retain
separate co-counsel at its sole cost and expense and participate in the defense
of the Third Party Claim.

                                         (3)     So long as the Indemnifying
Party has assumed and is conducting the defense of the Third Party Claim in
accordance with Section 9(c)(ii)(2) above, (A) the Indemnifying Party will not
consent to the entry of any judgment or enter into any settlement with respect
to the Third Party Claim without the prior written consent of the Claiming Party
(not to be withheld unreasonably) unless the judgment or proposed settlement
involves only the payment of money damages by the Indemnifying Party and does
not impose an injunction or other equitable relief upon the Claiming Party and
(B) the Claiming Party will not consent to the entry of any judgment or enter
into any settlement with respect to the Third Party Claim without the prior
written consent of the Indemnifying Party (not to be withheld unreasonably).

                                         (4)     In the event the Indemnifying
Party does not assume and conduct the defense of the Third Party Claim in
accordance with Section 9(c)(ii)(2) above, however, (A) the Claiming Party may
defend against, and consent to the entry of any judgment or enter into any
settlement with respect to, the Third Party Claim in any manner it reasonably
may deem appropriate (and the Claiming Party need not consult with, or obtain
any consent from, the Indemnifying Party in connection therewith) and (B) the
Indemnifying Party will remain responsible for any Losses the Claiming Party may
suffer resulting from, arising out of, relating to, in the nature of, or caused
by the Third Party Claim to the fullest extent provided in this Section 9.

               (d)     Determination of Amount of Claim for Indemnification. In
determining the amount of any and all Losses under this Section 9, such amount
shall be net of insurance proceeds actually received on account of such Loss.

    10.        Survival of Representations and Warranties. All representations
and warranties contained in this Agreement or made in writing by any party in
connection with this Agreement shall survive the execution and delivery of this
Agreement and the consummation of the transactions contemplated by this
Agreement for a period of three years (and thereafter shall be of no force or
effect), regardless of any investigation made by the Trust.

    11.        Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the Parties and their respective successors and
permitted assigns. No party may assign either this Agreement or any of its
rights, interests, or obligations under this Agreement without the prior written
approval of the other party.

6.

--------------------------------------------------------------------------------

    12.        Governing Law. This Agreement shall be governed by and construed
in accordance with the domestic laws of Florida without giving effect to any
choice or conflict of law provision or rule (whether of Florida or any other
jurisdiction) that would cause the application of the laws of any jurisdiction
other than Florida.

    13.        Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together shall constitute one and the same instrument.

    14.        Notice. All notices and other communications made pursuant to
this Agreement shall be in writing and will be sufficient if delivered by hand,
registered or certified mail (postage prepaid), or by overnight delivery
service, to the persons at the address set forth below (or at such other address
as may be provided in a notice delivered pursuant to this Section 14), and shall
be deemed effective as of the date delivered.

      If to the Company: If to the Siegel Family Revocable Trust

Medical Technology Systems, Inc.   Siegel Family Revocable Trust

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

Medical Technology Systems, Inc.   Siegel Family Revocable Trust 12920
Automobile Blvd.   10043 Windtree Boulevard Clearwater, Florida 33762  
Seminole, Florida 33772 Attention: Todd Siegel   Attention: Todd Siegel, as
Trustee of Siegel Family Revocable Trust Phone:  (727) 576-6311  
Phone:  (727) 576-6311 Facsimile:  (727) 540-0547   Facsimile:  (727) 573-1100

    15.        Amendment or Waiver. No amendment of any provision of this
Agreement shall be valid unless the same shall be in writing and signed by each
of the Parties. No waiver by either party to this Agreement of any default,
misrepresentation, or breach of warranty or covenant under this Agreement,
whether intentional or not, shall be deemed to extend to any prior or subsequent
default, misrepresentation, or breach of warranty or covenant under this
Agreement or affect in any way any rights arising by virtue of any prior or
subsequent such occurrence.

    16.        Entire Agreement. This Agreement constitutes the entire agreement
between the Parties and supersedes any prior understandings, agreements, or
representations by or between the Parties, written or oral, to the extent they
related in any way to the subject matter of this Agreement, including, without
limitation, the License Agreement.

    17.        Headings. The paragraph headings contained in this Agreement are
inserted for convenience only and shall not affect in any way the meaning or
interpretation of this Agreement.

    18.        Severability. Any term or provision of this Agreement that is
invalid or unenforceable in any situation in any jurisdiction shall not affect
the validity or enforceability of the remaining terms and provisions of this
Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdictin.

7.

--------------------------------------------------------------------------------

    19.        Expenses. Except as the Parties may otherwise mutually agree,
each of the Parties shall bear its own costs and expenses (including legal fees
and expenses) incurred in connection with this Agreement and the transactions
contemplated by this Agreement. Notwithstanding the foregoing sentence, all
sales, transfer, documentary and similar taxes, fees and assessments, if any,
payable in connection with the sale, conveyance, assignment, transfers and
deliveries made by the Trust or the Company in connection with this Agreement,
including, without limitation, the issuance of the Note, shall be paid by the
Company.

8.

--------------------------------------------------------------------------------

        IN WITNESS WHEREOF, the Parties have executed this Agreement effective
as of date first written above.

THE COMPANY      MEDICAL TECHNOLOGY SYSTEMS, INC.        By:

--------------------------------------------------------------------------------

         Name:

--------------------------------------------------------------------------------

         Title:

--------------------------------------------------------------------------------

     THE TRUST:       

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

  Todd Siegel, as Trustee of the Siegel Family Revocable Trust

9.

--------------------------------------------------------------------------------

EXHIBIT A

Company’s Promissory Note

PROMISSORY NOTE

$1,480,000   July 28, 2003

FOR VALUE RECEIVED the undersigned, Medical Technology Systems, Inc., a Delaware
corporation, with an address of 12920 Automobile Blvd., Clearwater, Florida
33762 (the “Debtor”), promises to pay to the Siegel Family Revocable Trust (the
“Holder”) at 10043 Windtree Boulevard, Seminole, Florida 33772 or at such other
address the Holder may designate, the principal sum of One Million Four Hundred
Eighty Thousand dollars ($1,480,000) plus interest on the outstanding principal
balance at the rate of 6.25% per annum, from the date of this Note until payment
is made in full.

        The principal of this Note shall be payable in sixty equal payments of
$28,784.92 (which includes accrued interest), payable monthly, beginning on
August 1, 2003 and ending on August 1, 2008.

        This Note may be prepaid at any time, in full or in part, without
penalty or premium. An event of default will occur under this Note if the Debtor
fails to make a payment before 5:00 p.m., eastern time, on the day such payment
is due. An event of default under this Note will become a default if not cured
within ten days of notice of such event of default is conveyed by the Holder to
the Debtor. In the case of a default, the Holder may declare the entire
principal amount of this Note, including accrued interest, immediately due and
payable. The Debtor shall pay all costs of collection, including reasonable
attorneys fees at all levels of proceedings.

        The Debtor and any other party liable for the payment of any amount due
under this Note waive presentment, protest and demand, notice of protest, and
dishonor. The Debtor and any other party liable for the payment of this Note
expressly consent to any extensions and renewals, in whole or in part, and all
delays in time of performance which the Holder may grant at any time and from
time to time, without limitation and without any notice or further consent of
such persons. Neither party shall assign this Note without the written consent
of the other party and such consent shall not be unreasonably withheld.

        No failure by the Holder to exercise any right or remedy shall be deemed
to be a waiver or release of such right or remedy, and any waiver or release may
be effected only through a written document executed by the Holder and then only
to the extent specifically recited in such document.

        This Note shall be governed by and construed under the laws of Florida,
without regard to principles of conflict of laws.

  MEDICAL TECHNOLOGY SYSTEMS, INC.           By:

--------------------------------------------------------------------------------

          Name:

--------------------------------------------------------------------------------

          Title::

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

EXHIBIT B

Assignment and Assumption Agreement

ASSIGNMENT AND ASSUMPTION AGREEMENT

        THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment”) is made and
entered as of July 28, 2003 between the Siegel Family Revocable Trust (the
“Trust”) and Medical Technology Systems, Inc., a Delaware corporation (the
“Company”).

BACKGROUND

        The Company and the Trust are entering into an Asset Purchase Agreement
(the “Asset Purchase Agreement”), dated as of the date of this Assignment,
whereby the Company is purchasing from the Trust the Patent Rights. The Company
and the Trust desire for the Trust to assign the Patent Rights to the Company,
and for the Company to accept such assignment of the Patent Rights. All
capitalized terms used but not otherwise defined herein shall have the meaning
ascribed to them in the Asset Purchase Agreement.

        In consideration of the foregoing and of the mutual covenants set forth
in this Assignment and other good and valuable consideration, the Parties agree
as follows:

TERMS

    1.        Assignment by the Trust. The Trust transfers and assigns to the
Company and its successors and assigns all of the Trust’s right, title and
interest in and to all of the Patent Rights.

    2.        Assumption by the Company. The Company accepts the assignment of
the Trust’s right, title and interest in and to the Patent Rights.

    3.        Further Assurances. It is the intention of the Parties that the
Patent Rights shall be transferred by the Trust to the Company and accepted from
the Trust, as provided in the Asset Purchase Agreement. The Parties therefore
agree that each shall execute any additional documents that may hereafter
reasonably be requested by the other in order to more fully to effectuate such
transfer, assignment, and assumption.

    4.        Governing Law. This Assignment shall be governed and controlled as
to validity, enforcement, interpretation, construction, effect and in all other
respects by the internal laws of Florida applicable to contracts made in
Florida.

    5.        Multiple Counterparts. This Assignment may be executed in any
number of counterparts, each of which shall be deemed an original instrument.
Facsimile copies of executed documents shall be deemed originals for all
purposes.

    6.        Binding Effect. This Assignment shall be binding upon and inure to
the benefit of the Parties and their successors and assigns. Except for the
Asset Purchase Agreement and the other closing documents executed by the Trust
and the Company pursuant to it, this Assignment records the entire understanding
between the parties regarding the assignment of the Patent Rights and supersedes
any previous or contemporaneous agreement, understanding, or representation,
oral or written, by either of them.

--------------------------------------------------------------------------------

        IN WITNESS WHEREOF, the Parties have executed this Assignment on the
date first above written.

THE COMPANY      MEDICAL TECHNOLOGY SYSTEMS, INC.        By:

--------------------------------------------------------------------------------

         Name:

--------------------------------------------------------------------------------

         Title:

--------------------------------------------------------------------------------

     THE TRUST:       

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

  Todd Siegel, as Trustee of the Siegel Family Revocable Trust

2.

--------------------------------------------------------------------------------

Patent Rights Schedule

Patent Description   U.S. Patent No.   Issue Date  

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

  1. Medication Blister Card   DES 306,825   03/27/90   2. Multi-Cavity
Medication Card Crusher (Deblister Machine)   4,694,996              09/22/87  
3. Dedicated Multi-Cavity Dispenser for Solids (MTS 300)   4,834,264           
  05/30/89   4. Slideable Dispenser for Solids (MTS 300) (Canadian)  
1,266,634              03/13/90   5. Sealing Apparatus (MTS 300)  
4,776,150              10/11/88   6. Medication Dispensing Identifier Method 
4,730,849              03/15/88   7. Medication Dispensing Identifier System  
4,732,411              03/22/88   8. Medication Compliance Aid for Unit Dose
Packaging (Gordon)   4,617,557              10/14/86  

S11-1